British journal of pharmacology |
Pubbl/distr/stampa | [London], : Nature Pub. Group |
Descrizione fisica | 1 online resource |
Disciplina | 615.1 |
Soggetto topico |
Pharmacology
Chemotherapy Drug Therapy Pharmacologie Chimiothérapie |
Soggetto genere / forma |
Periodical
Periodicals. |
ISSN | 1476-5381 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Periodico |
Lingua di pubblicazione | eng |
Altri titoli varianti | BJP |
Record Nr. | UNISA-996208197503316 |
[London], : Nature Pub. Group | ||
![]() | ||
Lo trovi qui: Univ. di Salerno | ||
|
British journal of pharmacology and chemotherapy |
Pubbl/distr/stampa | London, : British Medical Association |
Disciplina | 615.105 |
Soggetto topico |
Pharmacology
Chemotherapy Drug Therapy Chimiothérapie Pharmacologie pharmacology Pharmakologie |
Soggetto genere / forma |
Periodical
Periodicals. |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Periodico |
Lingua di pubblicazione | eng |
Record Nr. | UNISA-996204739603316 |
London, : British Medical Association | ||
![]() | ||
Lo trovi qui: Univ. di Salerno | ||
|
British journal of pharmacology and chemotherapy |
Pubbl/distr/stampa | London, : British Medical Association |
Disciplina | 615.105 |
Soggetto topico |
Pharmacology
Chemotherapy Drug Therapy Chimiothérapie Pharmacologie pharmacology Pharmakologie |
Soggetto genere / forma |
Periodical
Periodicals. |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Periodico |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910134572903321 |
London, : British Medical Association | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Cancer chemotherapy [[electronic resource] /] / Rachel Airley |
Autore | Airley Rachel |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 |
Descrizione fisica | 1 online resource (362 p.) |
Disciplina |
616.99/4061
616.994061 |
Soggetto topico |
Cancer - Chemotherapy
Chemotherapy |
ISBN |
1-282-11217-1
9786612112171 0-470-09254-8 0-470-09256-4 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Cancer Chemotherapy; Contents; Preface; 1 Cancer epidemiology; 1.1 Cancer incidence, prevalence and mortality; 1.2 Childhood cancers; 1.3 Global epidemiology; 2 Histopathology of cancer; 2.1 Introduction; 2.2 Malignant, benign and normal (non-malignant) tissue; 2.3 Cell death; 3 Carcinogenesis, malignant transformation and progression; 3.1 Introduction; 3.2 Chemical carcinogenesis; 4 Molecular biology of cancer: oncogenes and tumour suppressor genes; 4.1 Introduction; 4.2 Oncogenesis; 4.3 Tumour suppressor genes; 5 Tumour metastasis: a convergence of many theories; 5.1 Introduction
5.2 Detachment and migration from the primary tumour5.3 Intravasation; 5.4 Transport; 5.5 Extravasation; 5.6 Growth of the metastatic tumour mass; 6 Health professionals in the treatment of cancer; 6.1 Introduction; 6.2 Pathology; 6.3 Radiology; 6.4 Role of the surgical oncologist; 6.5 Oncology pharmacy; 6.6 Oncology nursing; 6.7 The NHS Cancer Plan; 7 Principles of cancer chemotherapy; 7.1 Introduction; 7.2 Timing of chemotherapy; 7.3 Biomarkers and their uses; 7.4 Clinical assessment of biomarkers; 7.5 Pharmacogenetics and pharmacogenomics of cancer chemotherapy 8 Classical anticancer agents8.1 Introduction; 8.2 Alkylating agents; 8.3 Antimetabolites; 8.4 Agents derived from natural or semisynthetic products; 8.5 Hormonal anticancer agents; 8.6 Clinically used chemotherapy regimens; 9 The philosophy of cancer research; 9.1 Introduction; 9.2 Structure of cancer research organizations in the United Kingdom; 9.3 Cancer research in the United States; 10 Novel anticancer agents; 10.1 Introduction; 10.2 Target validation; 10.3 Identification and optimization of lead drugs; 10.4 Preclinical pharmacology; 11 Clinical trials; 11.1 Introduction 11.2 Evaluation of treatment response11.3 Assessment of vascularity and angiogenesis by nuclear medicine technology; 12 Tumour hypoxia; 12.1 Introduction; 12.2 Bioreductive drugs; 12.3 Inhibitors of HIF-1 and HIF-1-regulated genes; 13 Antiangiogenic and antivascular agents; 13.1 History of angiogenesis as a therapeutic target; 13.2 Anti-angiogenic drug targets; 13.3 The return of thalidomide; 13.4 Monoclonal antibodies as anti-angiogenic agents; 13.5 The hollow fibre assay as a drug screen for anti-angiogenic drugs; 13.6 Vascular disrupting agents; 14 Tyrosine kinase inhibitors 14.1 Introduction14.2 Tyrosine kinase inhibitors targeting angiogenesis; 14.3 Non-receptor tyrosine kinase inhibitors; 15 Ras inhibitors; 16 Inhibitors of the Akt/PKB pathway; 17 Targeting stress proteins: HSP90 inhibitors; 18 The proteasome; 18.1 Introduction; 18.2 The proteasome as a target for novel drug strategies; 18.3 Ubiquitylation as a target; 19 Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR); 19.1 Mammalian target of rapamycin; 19.2 Structure and activation of mTOR; 19.3 Novel anticancer agents targeting mTOR; 20 Telomerase 21 Histone deacetylase: an epigenetic drug target |
Record Nr. | UNINA-9910782612503321 |
Airley Rachel
![]() |
||
Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Cancer chemotherapy / / Rachel Airley |
Autore | Airley Rachel |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 |
Descrizione fisica | 1 online resource (362 p.) |
Disciplina |
616.99/4061
616.994061 |
Soggetto topico |
Cancer - Chemotherapy
Chemotherapy |
ISBN |
1-282-11217-1
9786612112171 0-470-09254-8 0-470-09256-4 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Cancer Chemotherapy; Contents; Preface; 1 Cancer epidemiology; 1.1 Cancer incidence, prevalence and mortality; 1.2 Childhood cancers; 1.3 Global epidemiology; 2 Histopathology of cancer; 2.1 Introduction; 2.2 Malignant, benign and normal (non-malignant) tissue; 2.3 Cell death; 3 Carcinogenesis, malignant transformation and progression; 3.1 Introduction; 3.2 Chemical carcinogenesis; 4 Molecular biology of cancer: oncogenes and tumour suppressor genes; 4.1 Introduction; 4.2 Oncogenesis; 4.3 Tumour suppressor genes; 5 Tumour metastasis: a convergence of many theories; 5.1 Introduction
5.2 Detachment and migration from the primary tumour5.3 Intravasation; 5.4 Transport; 5.5 Extravasation; 5.6 Growth of the metastatic tumour mass; 6 Health professionals in the treatment of cancer; 6.1 Introduction; 6.2 Pathology; 6.3 Radiology; 6.4 Role of the surgical oncologist; 6.5 Oncology pharmacy; 6.6 Oncology nursing; 6.7 The NHS Cancer Plan; 7 Principles of cancer chemotherapy; 7.1 Introduction; 7.2 Timing of chemotherapy; 7.3 Biomarkers and their uses; 7.4 Clinical assessment of biomarkers; 7.5 Pharmacogenetics and pharmacogenomics of cancer chemotherapy 8 Classical anticancer agents8.1 Introduction; 8.2 Alkylating agents; 8.3 Antimetabolites; 8.4 Agents derived from natural or semisynthetic products; 8.5 Hormonal anticancer agents; 8.6 Clinically used chemotherapy regimens; 9 The philosophy of cancer research; 9.1 Introduction; 9.2 Structure of cancer research organizations in the United Kingdom; 9.3 Cancer research in the United States; 10 Novel anticancer agents; 10.1 Introduction; 10.2 Target validation; 10.3 Identification and optimization of lead drugs; 10.4 Preclinical pharmacology; 11 Clinical trials; 11.1 Introduction 11.2 Evaluation of treatment response11.3 Assessment of vascularity and angiogenesis by nuclear medicine technology; 12 Tumour hypoxia; 12.1 Introduction; 12.2 Bioreductive drugs; 12.3 Inhibitors of HIF-1 and HIF-1-regulated genes; 13 Antiangiogenic and antivascular agents; 13.1 History of angiogenesis as a therapeutic target; 13.2 Anti-angiogenic drug targets; 13.3 The return of thalidomide; 13.4 Monoclonal antibodies as anti-angiogenic agents; 13.5 The hollow fibre assay as a drug screen for anti-angiogenic drugs; 13.6 Vascular disrupting agents; 14 Tyrosine kinase inhibitors 14.1 Introduction14.2 Tyrosine kinase inhibitors targeting angiogenesis; 14.3 Non-receptor tyrosine kinase inhibitors; 15 Ras inhibitors; 16 Inhibitors of the Akt/PKB pathway; 17 Targeting stress proteins: HSP90 inhibitors; 18 The proteasome; 18.1 Introduction; 18.2 The proteasome as a target for novel drug strategies; 18.3 Ubiquitylation as a target; 19 Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR); 19.1 Mammalian target of rapamycin; 19.2 Structure and activation of mTOR; 19.3 Novel anticancer agents targeting mTOR; 20 Telomerase 21 Histone deacetylase: an epigenetic drug target |
Record Nr. | UNINA-9910825509203321 |
Airley Rachel
![]() |
||
Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Cancer of the Exocrine Pancreas : : From Oncogenes to Unresectable Tumors / / editor, J. Delmont |
Autore | Delmont J |
Pubbl/distr/stampa | Basel : , : S. Karger, , 1986 |
Descrizione fisica | 1 online resource (X + 360 pages) : : 74 figures, 1 in color, 55 tables |
Collana | Frontiers of Gastrointestinal Research |
Soggetto topico |
Gastroenterology
Oncology Surgery Biochemistry Chemotherapy Epidemiology Histology Pathology |
ISBN | 3-318-03635-8 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910157469203321 |
Delmont J
![]() |
||
Basel : , : S. Karger, , 1986 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Carcinogenesis and Adducts in Animals and Humans : : Workshop, Cambridge, Mass., February 1986 / / editors, M.C. Poirier, F.A. Beland |
Autore | Poirier M.C |
Pubbl/distr/stampa | Basel : , : S. Karger, , 1987 |
Descrizione fisica | 1 online resource (VIII + 116 pages) : : 39 figures, 1 in color, 10 tables |
Soggetto topico |
Oncology
Pharmacology Biochemistry Chemotherapy Epidemiology Toxicology |
ISBN | 3-318-04184-X |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910158700003321 |
Poirier M.C
![]() |
||
Basel : , : S. Karger, , 1987 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Chemoradiotherapy : concurrent uses, efficacy and impact on prognosis / / Daniel Sullivan, editor |
Pubbl/distr/stampa | Hauppauge, NY : , : Nova Science Publishers, Incorporated, , [2017] |
Descrizione fisica | 1 online resource (81 pages) |
Collana | Cancer etiology, diagnosis and treatments |
Soggetto topico | Chemotherapy |
ISBN | 1-5361-0722-0 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910159433803321 |
Hauppauge, NY : , : Nova Science Publishers, Incorporated, , [2017] | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Chemosensitivity Testing in Gynecologic Malignancies and Breast Cancer / / editors, O.R. Köchli, B.U. Sevin, U. Haller |
Autore | Köchli O.R |
Pubbl/distr/stampa | Basel : , : S. Karger, , 1994 |
Descrizione fisica | 1 online resource (X + 200 pages) : : 42 figures, 1 in color, 30 tables |
Collana | Contributions to Gynecology and Obstetrics |
Soggetto topico |
Obstetrics
Gynecology Oncology Biology for Physicians Chemotherapy Laboratory Pathology Surgery |
ISBN | 3-318-03242-5 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910155265303321 |
Köchli O.R
![]() |
||
Basel : , : S. Karger, , 1994 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Chemotherapie - Kompendium für das Pflegepersonal / / A. Löser, B. Löser |
Autore | Löser A |
Pubbl/distr/stampa | Basel : , : S. Karger, , 1990 |
Descrizione fisica | 1 online resource (VIII + 50 pages) : : 3 figures, 4 tables |
Soggetto topico |
Pharmacology
Nursing Pharmaceutics Chemotherapy |
ISBN | 3-318-04414-8 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | ger |
Record Nr. | UNINA-9910149606903321 |
Löser A
![]() |
||
Basel : , : S. Karger, , 1990 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|